Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Outlook Therapeutics, Inc.

OTLK · Nasdaq · CIK 0001649989 · Healthcare · Biotechnology

INSIDER SIGNAL

83.9 / 100

7 buyers · 10 purchase transaction lines · $7.9M gross purchase

WHY THIS SIGNAL?

Buyer breadthStrong
Purchase sizeStrong
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+35.0 / 35
Purchase size+22.5 / 25
Role+13.0 / 20
Recency+3.4 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent
  • ✓ Cluster breadth is broad · 4+ insiders

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Haddadin Yezan MuntherDirector
●●
GMS Ventures & Investments; Sukhtian Ghiath M.Director,TenPercentOwner
●●
Sukhtian Faisal GhiathDirector
●●
THURMAN RANDY HDirector
●
HILZINGER KURT JDirector
●
Jahr Robert CharlesChief Executive Officer
●
● Purchase▼ Sale○ Other

Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS7
PURCHASE CONCENTRATION95%Largest buyer: GMS Ventures & Investments; Sukhtian Ghiath M. · $7.5M
CLUSTER BUYING · 15D5 insidersPeak activity: 2026-05-26–2026-06-02

Roles in the peak window: Director, Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

83.9 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 84.3
  2. 84.2
  3. 84.1
  4. 84.0
  5. 83.9

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

10Purchases
0Sales
0Other Form 4 lines
10SEC filings · 365 days
BUYING10 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-9.4%
3M
-61.4%
6M
+140.6%
12M
-52.5%

Volatility & liquidity

Volatility
138.9%
Beta
—
Avg daily value
USD 8.0M

Valuation

Market cap
USD 145.8M
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-14 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
31,896,591
Previous report
32,220,502
Avg daily volume
4,488,940
Days to cover
7.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-14KENYON LAWRENCE APurchase (P)Common Stock101,010USD —USD —SEC filing ↗
2026-08-14Jahr Robert CharlesPurchase (P)Common Stock151,515USD —USD —SEC filing ↗
2026-08-12GMS Ventures & Investments; Sukhtian Ghiath M.Purchase (P)Common Stock2,525,252USD 0.99USD 2,499,999SEC filing ↗
2026-07-29Sukhtian Faisal GhiathPurchase (P)Common Stock95,398USD 1.05USD 100,168SEC filing ↗
2026-06-02Haddadin Yezan MuntherPurchase (P)Common Stock29,000USD 0.83USD 24,070SEC filing ↗
2026-05-28GMS Ventures & Investments; Sukhtian Ghiath M.Purchase (P)Common Stock8,539,709USD 0.59USD 5,038,428SEC filing ↗
2026-05-27Sukhtian Faisal GhiathPurchase (P)Common Stock122,174USD 0.41USD 50,091SEC filing ↗
2026-05-26THURMAN RANDY HPurchase (P)Common Stock5,000USD 0.43USD 2,150SEC filing ↗
2026-05-26Haddadin Yezan MuntherPurchase (P)Common Stock34,000USD 0.44USD 14,960SEC filing ↗
2026-05-26HILZINGER KURT JPurchase (P)Common Stock400,000USD 0.44USD 176,000SEC filing ↗
2024-09-26KENYON LAWRENCE APurchase (P)Common Stock5,000USD 5.69USD 28,450SEC filing ↗
2024-04-15Syntone Ventures LLCPurchase (P)Common Stock714,286USD —USD —SEC filing ↗
2024-03-28Haddadin Yezan MuntherPurchase (P)Common Stock1,882USD 11.82USD 22,242SEC filing ↗
2024-03-07Evanson JeffPurchase (P)Common Stock62,484USD 0.42USD 26,243SEC filing ↗
2022-10-07Sukhtian Faisal GhiathPurchase (P)Common Stock30,000USD 1.29USD 38,700SEC filing ↗

Form 4 evidence

10 transaction lines in the latest 365-day window; 70 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-14KENYON LAWRENCE APurchase (P)Common Stock101,010USD —USD —SEC filing ↗
2026-08-14Jahr Robert CharlesPurchase (P)Common Stock151,515USD —USD —SEC filing ↗
2026-08-12GMS Ventures & Investments; Sukhtian Ghiath M.Purchase (P)Common Stock2,525,252USD 0.99USD 2,499,999SEC filing ↗
Show recent Form 4 evidence (10 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-14KENYON LAWRENCE APurchase (P)Common Stock101,010USD —USD —SEC filing ↗
2026-08-14Jahr Robert CharlesPurchase (P)Common Stock151,515USD —USD —SEC filing ↗
2026-08-12GMS Ventures & Investments; Sukhtian Ghiath M.Purchase (P)Common Stock2,525,252USD 0.99USD 2,499,999SEC filing ↗
2026-07-29Sukhtian Faisal GhiathPurchase (P)Common Stock95,398USD 1.05USD 100,168SEC filing ↗
2026-06-02Haddadin Yezan MuntherPurchase (P)Common Stock29,000USD 0.83USD 24,070SEC filing ↗
2026-05-28GMS Ventures & Investments; Sukhtian Ghiath M.Purchase (P)Common Stock8,539,709USD 0.59USD 5,038,428SEC filing ↗
2026-05-27Sukhtian Faisal GhiathPurchase (P)Common Stock122,174USD 0.41USD 50,091SEC filing ↗
2026-05-26THURMAN RANDY HPurchase (P)Common Stock5,000USD 0.43USD 2,150SEC filing ↗
2026-05-26Haddadin Yezan MuntherPurchase (P)Common Stock34,000USD 0.44USD 14,960SEC filing ↗
2026-05-26HILZINGER KURT JPurchase (P)Common Stock400,000USD 0.44USD 176,000SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerOTLK
CIK0001649989
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history70 transaction lines from 2020-01-29 to 2026-08-14
46 P purchase lines · 9 S sale lines · 15 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.